420 related articles for article (PubMed ID: 24723493)
21. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
22. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Faderl S; Thomas DA; O'Brien S; Garcia-Manero G; Kantarjian HM; Giles FJ; Koller C; Ferrajoli A; Verstovsek S; Pro B; Andreeff M; Beran M; Cortes J; Wierda W; Tran N; Keating MJ
Blood; 2003 May; 101(9):3413-5. PubMed ID: 12522009
[TBL] [Abstract][Full Text] [Related]
23. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Tsimberidou AM; Tam C; Abruzzo LV; O'Brien S; Wierda WG; Lerner S; Kantarjian HM; Keating MJ
Cancer; 2009 Jan; 115(2):373-80. PubMed ID: 19117034
[TBL] [Abstract][Full Text] [Related]
24. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
Tam CS; Shanafelt TD; Wierda WG; Abruzzo LV; Van Dyke DL; O'Brien S; Ferrajoli A; Lerner SA; Lynn A; Kay NE; Keating MJ
Blood; 2009 Jul; 114(5):957-64. PubMed ID: 19414856
[TBL] [Abstract][Full Text] [Related]
25. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
26. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
28. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
Kay NE; LaPlant BR; Pettinger AM; Call TG; Leis JF; Ding W; Parikh SA; Conte MJ; Bowen DA; Shanafelt TD
Expert Rev Hematol; 2018 Apr; 11(4):337-349. PubMed ID: 29460654
[TBL] [Abstract][Full Text] [Related]
29. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.
Zent CS; Call TG; Bowen DA; Conte MJ; LaPlant BR; Witzig TE; Ansell SM; Weiner GJ
Leuk Lymphoma; 2015; 56(8):2373-8. PubMed ID: 25676035
[TBL] [Abstract][Full Text] [Related]
30. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia
Davids MS; Kim HT; Yu L; De Maeyer G; McDonough M; Vartanov AR; Langey R; Fernandes SM; Hellman JM; Francoeur K; Arnason J; Jacobsen ED; LaCasce AS; Fisher DC; Brown JR
Leuk Lymphoma; 2019 May; 60(5):1312-1315. PubMed ID: 30322319
[TBL] [Abstract][Full Text] [Related]
32. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract][Full Text] [Related]
33. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
34. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
35. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
[TBL] [Abstract][Full Text] [Related]
36. Current and emerging treatments for chronic lymphocytic leukaemia.
Robak T; Jamroziak K; Robak P
Drugs; 2009; 69(17):2415-49. PubMed ID: 19911856
[TBL] [Abstract][Full Text] [Related]
37. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
[TBL] [Abstract][Full Text] [Related]
38. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Woyach JA; Lin TS; Lucas MS; Heerema N; Moran ME; Cheney C; Lucas DM; Wei L; Caligiuri MA; Byrd JC
Leukemia; 2009 May; 23(5):912-8. PubMed ID: 19225537
[TBL] [Abstract][Full Text] [Related]
39. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
Kay NE; Wu W; Kabat B; LaPlant B; Lin TS; Byrd JC; Jelinek DF; Grever MR; Zent CS; Call TG; Shanafelt TD
Cancer; 2010 May; 116(9):2180-7. PubMed ID: 20187101
[TBL] [Abstract][Full Text] [Related]
40. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
